The recent hospitalisation of Madonna once again highlights the risks posed by bacterial infections and their potentially serious consequences for patients.
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh